Find Your Daily Voice
Norwalk
Your Local News for Norwalk and Rowayton, Connecticut
Saturday, nov 16
53°
Follow
News
Schools
Business
Obituaries
Police & Fire
Weather
Lifestyle
Politics
Sports
Events
Real Estate
Tags
Jobs
Shop
Support Us
Norwalk
Follow
Find Your Daily Voice
News
Schools
Business
Obituaries
Police & Fire
Weather
Lifestyle
Politics
Sports
Events
Real Estate
Tags
Jobs
Shop
Support Us
Home
About us
All sites
Advertise with us
Contact us
Terms of use
Privacy policy
Code of ethics
Site Map
© 2024 Cantata Media
53°
Saturday, nov 16
Tag:
Albert Bourla
News
Covid-
19: Pfizer Asks FDA For Emergency Use Authorization Of Vaccine For Children Under 5
New York-based Pfizer and its European partner BioNTech has requested that the Food and Drug Administration (FDA) expand the use of its COVID-19 vaccine to include children between the ages of 6 months and 5 years old, officials announced. On Tuesday, Feb. 1, citing a host of clinical trials, the pharmaceutical company announced it is seeking emergency use authorization (EUA) to admit the vaccine to a wider range of children. Currently, the vaccine is only approved for children 5 years old and older. Pfizer said that it plans to complete its EUA submission “in the coming days,” and has alre…
News
Covid-
19: Pfizer CEO Announces When Vaccine Targeting Omicron Variant Will Be Ready
A vaccine targeting the highly transmissible Omicron COVID-19 variant could be on the way from Pfizer. On Monday, Jan. 10, Pfizer CEO Albert Bourla said that booster targeting Omicron will be ready as soon as March, as the company has already begun ramping up production of the doses. “This vaccine will be ready in March,” Bourla told CNBC’s “Squawk Box.” “We (are) already starting manufacturing some of these quantities at risk.” Related story - COVID-19: Fauci Offers New Prediction On When Omicron Wave May Break The vaccine will not exclusively target Omicron, but will also be able to fig…
News
Covid-
19: FDA Expands Pfizer Booster Eligibility Among Adolescents As Omicron Cases Skyrocket
As the Omicron COVID-19 variant rages across the country, federal health officials have expanded the eligibility for booster shots in younger Americans. The Food and Drug Administration (FDA) announced on Monday, Jan. 3 that it is expanding the eligibility for Pfizer and BioNTech booster shots to American between the ages of 12 and 15 years old as children return to school amid a surge of new COVID-19 infections. FDA vaccine chief Dr. Peter Marks said in a statement the agency made its decision because a booster “may help provide better protection against both the delt…
News
Covid-
19: FDA OKs First Authorized Home Treatment For Virus
The fight against COVID-19 took a step forward as federal health officials authorized the first pill that Americans will be able to take at home to head off the worst effects of the virus. On Wednesday, Dec. 22, the US Food and Drug Administration (FDA) granted emergency authorization for Pfizer’s COVID-19 treatment pill, which has been recommended for people at high risk of developing severe cases of COVID-19. The pill could be available as soon as this weekend, according to Pfizer CEO Albert Bourla. Related story - COVID-19: Pfizer Releases Data On Anti-Viral Pill's Effective…
News
Covid-
19: Pfizer Releases Data On Anti-Viral Pill's Effectiveness Vs. Omicron, Severe Disease
Brand-new laboratory studies are shedding light on the effectiveness of Pfizer's anti-viral COVID-19 pill both against the Omicron variant and in warding off severe disease. The studies showed the pill, called Paxlovid, reduced the risk of hospitalization or death by nearly 90 percent if given to high-risk adults within several days of their initial COVID symptoms, Pfizer said in a statement released Tuesday morning, Dec. 14. The pill also retains activity against variants, including Omicron, because the drug blocks an enzyme involved in viral replication, Pfizer said. “Emerging …
News
Covid-
19: Fourth Shot May Eventually Be Needed, Pfizer Says
The CEO of Pfizer said in an interview that he believes a fourth COVID-19 vaccine dose will eventually be needed. Albert Bourla said on CNBC that real-world data will help determine how well three doses of the vaccine protect against the Omicron variant and how long protection lasts. "And the second point, I think we will need the fourth dose," Bourla told CNBC on Wednesday, Dec. 8. "I’ve said that multiple times. With the previous, I was projecting that that will be on 12 months after the third dose. With Omicron, we need to wait and see because we have very little informat…
News
Covid-
19: First Findings Released On Vaccine Effectiveness Against Omicron Variant
The first findings on the effectiveness of vaccines against the COVID-19 Omicron variant have been released. Pfizer and its European partner BioNTech said that a booster shot offers significant protection against Omicron and "neutralizes" the strain. Two vaccine doses "show significantly reduced neutralization titers" but could protect against severe disease from COVID, the companies said. The findings come from an initial laboratory study. According to the companies’ preliminary data, "a third dose provides a similar level of neutralizing antibodies to Omicron as is observ…
News
Covid-
19: Pfizer CEO Says New Vaccine May Be Needed For Omicron, Anti-Viral Pills Are Effective
Pfizer CEO Albert Bourla said that his company is preparing to tackle new COVID-19 variants, and that he expects the company’s treatment pill will be effective in helping avoid severe illness or possibly death if one get infected. According to the World Health Organization (WHO), Omicron poses a “very high” global risk, with the likelihood it is more transmissible than previous strains. The new variant has nearly three dozen mutations that reportedly decrease antibody protection. WHO described Omicron as a “highly divergent variant with a high number of mutations ... some of which are conce…
Business
Covid-
19: People Who Spread Misinfo About Vaccines Are ‘Criminals,' Pfizer CEO Says
Pfizer CEO Albert Bourla has harsh words for the “criminals” who have intentionally spread misinformation about COVID-19 vaccines. Speaking with Atlantic Council think tank CEO Frederick Kempe this week, Bourla said that a “very small” group of people spreading misinformation has cost millions of lives. “These people are criminals,” Bourla said. “They’re not bad people. They’re criminals because they have literally cost millions of lives.” Related story - COVID-19: Pfizer Expected To Seek Approval For Boosters For All Adults Bourla went on to say that “the only thing that stands betw…
News
Covid-
19: New Time Frame Provided For When Vaccine Booster Shots May Be Necessary
Executives and experts at the center of COVID-19 pandemic response are now providing a more specific possible time frame for when Americans who were first to receive a vaccine dose may need to take a booster shot. Pfizer CEO Albert Bourla, speaking during an Axios event, said that the data he has reviewed supports the notion "that likely there will be a need for a booster somewhere between eight and 12 months" after the initial vaccination regime. That means those who were among the first to get a vaccine shot in mid to late December 2020 or early January 2021 would likely need a booster sh…
News
Covid-
19: Pfizer Seeks Federal Approval To Market Vaccine Directly To Consumers
Pfizer and European partner company BioNTech are seeking full approval from the federal government to market their two-dose COVID-19 vaccine directly to people age 16 and over, as well as businesses and schools. The vaccine has been available in the United States since mid-December under an Emergency Use Authorization waiver by the Food and Drug Administration. Since then, the companies have delivered more than 170 million doses of the vaccine across the United States. “We are proud of the tremendous progress we’ve made since December in delivering vaccines to millions of Americans, in col…
News
Covid-
19: Pfizer CEO Reveals When Vaccine Booster Shot Likely Will Be Needed After Second Dose
Pfizer CEO Albert Bourla is cautioning that patients will likely need a third dose of the company’s COVID-19 vaccine within the next year to maintain the shot’s efficacy. During a recently aired interview, Bourla said that patients will “likely” need an additional dose of the vaccine within 12 months of becoming fully vaccinated with the two required doses. Bourla said that they are continuing to monitor the situation, and as more COVID-19 variants arise, the company may be forced to shift gears. “We need to see what would be the sequence, and for how often we need to do that, that remains…
Business
Covid-
19: Pfizer Dramatically Ramps Up Distribution After Pause On Johnson & Johnson Vaccines
Hundreds of millions of new COVID-19 vaccines are set to be distributed across the country as Pfizer prepares to ramp up the production of its doses amid the pause of the Johnson & Johnson one-dose shot rollout. Pfizer CEO Albert Bourla announced that his company, with headquarters in the New York (in Manhattan and Rockland County), is now on track to deliver 10 percent more vaccine doses to the US (approximately 220 million) while supplying the already agreed upon 300 million doses for the end of July two weeks early. Both Pfizer and Moderna, two of the three approved vaccines by the F…
News
Covid-
19: Pfizer Will Seek Vaccine Rollout For Younger Teens After Encouraging Trial Results
Clinical trials of the Pfizer/BioNTech’s COVID-19 vaccine showed that it has a 100 percent efficacy in adolescents and is well-tolerated in minors between the ages of 12 and 15, paving the way for distribution, the companies announced. Officials said that initial trials were fruitful, and they plan to submit the data to the U.S. Food and Drug Administration for expanded emergency use authorization of the two-dose vaccine in adolescents. According to Pfizer, the third phase of the clinical trial included 2,260 participants between the ages of 12 and 15, which found that strong antibody respo…
News
Covid-
19: Pfizer Boasts Vaccine Candidate That's More Than 90% Effective
More reliable than the flu shot? Pfizer on Monday trumpeted a COVID-19 vaccine candidate as more than 90% effective – nearly three times better than the effectiveness of last season’s influenza vaccine. Pfizer said it hopes to have 50 million doses of the free vaccine ready by the end of this year and as many as 1.3 billion doses available next year to fight the deadly global pandemic. Two doses per person of BNT162b2 would be necessary, said the Manhattan-based drug maker, which teamed up with BioNTech of Germany to develop the booster. Pfizer plans to ask the federal Food and Drug Admini…
53°
